Arcadia Biosciences Files 10-Q for Q2 2024

TL;DR

Arcadia Biosciences filed its Q2 10-Q. Check financials.

AI Summary

Arcadia Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations. Specific financial figures and operational details are available within the full filing.

Why It Matters

This filing provides investors with a detailed look at Arcadia Biosciences' financial health and operational performance for the second quarter of 2024, influencing investment decisions.

Risk Assessment

Risk Level: medium — As a publicly traded company, Arcadia Biosciences is subject to market fluctuations and business-specific risks detailed in its SEC filings.

Key Numbers

• 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 2024-08-13 — Filing Date (The date the report was officially submitted to the SEC.)

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Filer of the 10-Q
• 2024-06-30 (date) — End of reporting period
• 2024-08-13 (date) — Filing date
• 0000950170-24-096439 (accession_number) — Unique identifier for the filing

FAQ

Key Financial Figures

• $0.001 — 840 shares of common stock outstanding, $0.001 par value per share. Arcadia Bioscien

Filing Documents

• rkda-20240630.htm (10-Q) — 2462KB
• rkda-ex10_5.htm (EX-10.5) — 307KB
• rkda-ex31_1.htm (EX-31.1) — 13KB
• rkda-ex31_2.htm (EX-31.2) — 13KB
• rkda-ex32_1.htm (EX-32.1) — 8KB
• rkda-ex32_2.htm (EX-32.2) — 8KB
• 0000950170-24-096439.txt ( ) — 12243KB
• rkda-20240630.xsd (EX-101.SCH) — 1769KB
• rkda-20240630_htm.xml (XML) — 2568KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 Part II — Other Information 29 Item 1.

Legal Proceedings

Legal Proceedings 29 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 30

CONDENSED CONSOLID ATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLID ATED FINANCIAL STATEMENTS Arcadia Biosciences, Inc. Condensed Consolida ted Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 5,504 $ 6,518 Short-term investments 2,604 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $ 0 as of June 30, 2024 and December 31, 2023 840 506 Inventories — current 978 837 Assets held for sale — 51 Note receivable — current 1,759 — Prepaid expenses and other current assets 537 807 Current assets of discontinued operations — GoodWheat 212 1,129 Total current assets 12,434 14,972 Property and equipment, net 54 70 Right of use asset 513 792 Inventories — noncurrent 191 196 Intangible assets, net 39 39 Note receivable — noncurrent 3,974 — Other noncurrent assets 164 164 Noncurrent assets of discontinued operations — GoodWheat — 3,472 Total assets $ 17,369 $ 19,705 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 1,560 $ 1,910 Amounts due to related parties 80 58 Operating lease liability — current 563 852 Other current liabilities 255 270 Current liabilities of discontinued operations — GoodWheat 240 500 Total current liabilities 2,698 3,590 Operating lease liability — noncurrent 11 155 Common stock warrant and option liabilities 1,094 1,257 Other noncurrent liabilities 2,000 2,000 Total liabilities 5,803 7,002 Commitments and contingencies (Note 14) Stockholders' equity: Common stock, $ 0.001 par value— 150,000,000 shares authorized; 1,362,840 and 1,285,337 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 65 65 Additional paid-in capital 284,760 284,515 Accumulated other comprehensive in

View Full Filing

View this 10-Q filing on SEC EDGAR